EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Distinct immunophenotypic and clinical features of TP53-mutated acute myeloid leukemia: high CD34/CD41 expression and lower leukocyte counts

Songyi Park, Sang-A Kim, Sheehyun Kim, Seon Young Kim, Ji Yun Lee, Ja Min Byun, Sang Mee Hwang, Jeong-Ok Lee, Youngil Koh, Junshik Hong, Yoon Hwan Chang, Hyun Kyung Kim und 4 weitere

Annals of Hematology · 21.04.2026 · 105 (5)

DOI: 10.1007/s00277-026-07001-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 21.04.2026. Verfasst von Songyi Park und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University (SMG-SNU) Boram…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Antigens, CD34, Tumor Suppressor Protein p53, Mutation. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seoul National University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study investigates the clinical and molecular characteristics of TP53 -mutated acute myeloid leukemia (AML), associated with a poor prognosis. A retrospective analysis was conducted on 336 AML patients, focusing on the distinctions between TP53 -mutated and non-mutated cases. Our findings reveal that TP53 mutations are linked to a higher proportion of leukemic blasts positive for the primitive stem cell markers CD34 and CD41 (with dual positive: 12.5% vs. 1.3%, p < 0.001), suggesting a more stem/progenitor cell-like nature. Patients with TP53 -mutated AML exhibited lower white blood cell counts in peripheral blood ( p = 0.016) and reduced blast proportion in bone marrow (with a median of 39.6% in TP53 -mutated AML and 56.9% in TP53 wild-type AML, p = 0.01) at diagnosis. TP53 -mutated AML was frequently found in therapy-related AML cases and occurred with fewer concurrent genetic mutations compared to non-mutated AML. In terms of outcomes, TP53 mutations corresponded with significantly lower composite complete response rates and shorter overall and progression-free survival. This study highlights the distinct clinical, molecular, and immunophenotypic features of TP53-mutated AML and emphasizes the need for improved therapeutic strategies for this high-risk subtype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteAntigens, CD34Tumor Suppressor Protein p53MutationHumansFemaleMaleMiddle AgedAdultAgedRetrospective StudiesImmunophenotypingLeukocyte CountYoung AdultAged, 80 and overAdolescent

Stichwörter der Autor:innen

TP53 mutationAcute myeloid leukemia

Substanzen

Antigens, CD34Tumor Suppressor Protein p53TP53 protein, human

Autor:innen und Institutionen

  • Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University (SMG-SNU) Boramae Medical Center, Seoul, 07061, Republic of Korea.
  • Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, 13620, Gyeonggi-do, Republic of Korea.
  • Center for Precision Medicine, Seoul National University Hospital, Seoul, 03080, Republic of Korea.
  • Center for Medical Innovation, Clinical Research Institute, Seoul National University Hospital, Seoul, 03080, Republic of Korea.
  • Department of Laboratory Medicine, Seoul National University Hospital, Seoul, 03080, Republic of Korea.
  • Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, 03080, Republic of Korea.

Förderung

  • Seoul National University

Zitieren

APA

Park, S., Kim, S. A., Kim, S., Kim, S. Y., Lee, J. Y., Byun, J. M., Hwang, S. M., Lee, J. O., Koh, Y., Hong, J., Chang, Y. H., Kim, H. K., Bang, S. M., Kim, I., Yoon, S. S., & Shin, D. Y. (2026). Distinct immunophenotypic and clinical features of TP53-mutated acute myeloid leukemia: high CD34/CD41 expression and lower leukocyte counts. Annals of Hematology, 105(5). https://doi.org/10.1007/s00277-026-07001-4

Vancouver

Park S, Kim SA, Kim S, Kim SY, Lee JY, Byun JM, et al. Distinct immunophenotypic and clinical features of TP53-mutated acute myeloid leukemia: high CD34/CD41 expression and lower leukocyte counts. Annals of Hematology. 2026;105(5). doi:10.1007/s00277-026-07001-4

BibTeX
@article{Park2026,
  author = {Park, Songyi and Kim, Sang-A and Kim, Sheehyun and Kim, Seon Young and Lee, Ji Yun and Byun, Ja Min and Hwang, Sang Mee and Lee, Jeong-Ok and Koh, Youngil and Hong, Junshik and Chang, Yoon Hwan and Kim, Hyun Kyung and Bang, Soo-Mee and Kim, Inho and Yoon, Sung-Soo and Shin, Dong-Yeop},
  title = {Distinct immunophenotypic and clinical features of TP53-mutated acute myeloid leukemia: high CD34/CD41 expression and lower leukocyte counts},
  journal = {Annals of Hematology},
  year = {2026},
  volume = {105},
  number = {5},
  doi = {10.1007/s00277-026-07001-4}
}
Kostenlos starten →